The global robotic radiotherapy market size was valued at USD 1.37 billion in 2024 and is projected to reach USD 3.30 billion by 2033, growing at a CAGR of 10.36% from 2025 to 2033. The industry is primarily driven by the rising prevalence of cancer worldwide, the growing demand for highly precise and minimally invasive treatment options, advancements in image-guided and robot-assisted radiotherapy technologies and increasing adoption of personalized medicine approaches.
The healthcare infrastructure expansion in emerging markets, favorable reimbursement policies in developed regions, and the ability of robotic systems to reduce treatment times and improve patient outcomes further accelerate market growth.
The increasing prevalence of cancer cases is a key factor driving the market's growth. According to the WHO article published in February 2024, Global cancer cases are projected to exceed 35 million by 2050, representing a 77% increase from the 20 million cases reported in 2022. This sharp rise fuels the need for exact and efficient treatment options, driving stronger adoption of robotic radiotherapy systems. With growing patient volumes and increasing treatment complexity, robotic platforms are becoming essential due to their accuracy, automation, and ability to minimize damage to healthy tissues.
According to the American Cancer Society, in collaboration with IARC, there were about 20 million new cancer diagnoses in 2022 and 9.7 million cancer-related deaths. These data highlight the enormous and growing demand for healthcare systems globally. This escalating cancer burden fuels the adoption of robotic radiotherapy, as such platforms offer high-precision, minimally invasive treatments that can spare healthy tissue, reduce toxicity, and support efficient, automated workflows.
The increasing adoption of incision-free oncology treatment platforms is driving growth in the robotic radiotherapy market. For example, in August 2024, Apollo Cancer Centre in Bengaluru adopted the CyberKnife S7 FIM platform, reflecting the growing shift toward robotics-enabled radiosurgery capable of treating tumors across multiple regions of the body without incisions. Similarly, Tampa General Hospital introduced its upgraded CyberKnife S7 system in January 2024, highlighting the move toward outpatient-friendly radiation therapy delivered in significantly fewer sessions. These developments demonstrate how healthcare providers are prioritizing advanced robotic systems to enhance treatment accuracy, reduce session times, and improve patient convenience. The ability to deliver highly focused radiation in just a few outpatient visits allows patients to return home the same day or next, reinforcing the demand for precise, minimally invasive therapies that streamline oncology workflows.
Several developed markets are adopting supportive reimbursement policies for advanced radiotherapy. For instance, in the US, insurance coverage increasingly includes AI-driven robotic and stereotactic radiotherapy procedures. Policy incentives promote outpatient, precise cancer therapies, encouraging hospitals to invest in these high-tech platforms. Recent updates in states such as Arizona (effective August 2025) include reimbursement rules emphasizing radiation therapy management and dosimetry services critical to adaptive therapy, supporting advanced treatment adoption. These incentives help accelerate robotic radiotherapy penetration at oncologic centers by offsetting technology costs and encouraging precision care.
The industry has attracted significant investment, reflecting strong confidence in AI-powered, adaptive, and patient-centric treatment technologies. Funding is driving innovation in real-time imaging, adaptive treatment planning, and robotic delivery, enabling improved tumor targeting, workflow efficiency, and minimally invasive, outpatient-friendly therapies. Overall, this investment activity underscores growing investor confidence in technologies that enhance clinical outcomes and accelerate the adoption of advanced robotic radiotherapy worldwide.
This product will be delivered within 1-3 business days.
The healthcare infrastructure expansion in emerging markets, favorable reimbursement policies in developed regions, and the ability of robotic systems to reduce treatment times and improve patient outcomes further accelerate market growth.
The increasing prevalence of cancer cases is a key factor driving the market's growth. According to the WHO article published in February 2024, Global cancer cases are projected to exceed 35 million by 2050, representing a 77% increase from the 20 million cases reported in 2022. This sharp rise fuels the need for exact and efficient treatment options, driving stronger adoption of robotic radiotherapy systems. With growing patient volumes and increasing treatment complexity, robotic platforms are becoming essential due to their accuracy, automation, and ability to minimize damage to healthy tissues.
According to the American Cancer Society, in collaboration with IARC, there were about 20 million new cancer diagnoses in 2022 and 9.7 million cancer-related deaths. These data highlight the enormous and growing demand for healthcare systems globally. This escalating cancer burden fuels the adoption of robotic radiotherapy, as such platforms offer high-precision, minimally invasive treatments that can spare healthy tissue, reduce toxicity, and support efficient, automated workflows.
The increasing adoption of incision-free oncology treatment platforms is driving growth in the robotic radiotherapy market. For example, in August 2024, Apollo Cancer Centre in Bengaluru adopted the CyberKnife S7 FIM platform, reflecting the growing shift toward robotics-enabled radiosurgery capable of treating tumors across multiple regions of the body without incisions. Similarly, Tampa General Hospital introduced its upgraded CyberKnife S7 system in January 2024, highlighting the move toward outpatient-friendly radiation therapy delivered in significantly fewer sessions. These developments demonstrate how healthcare providers are prioritizing advanced robotic systems to enhance treatment accuracy, reduce session times, and improve patient convenience. The ability to deliver highly focused radiation in just a few outpatient visits allows patients to return home the same day or next, reinforcing the demand for precise, minimally invasive therapies that streamline oncology workflows.
Several developed markets are adopting supportive reimbursement policies for advanced radiotherapy. For instance, in the US, insurance coverage increasingly includes AI-driven robotic and stereotactic radiotherapy procedures. Policy incentives promote outpatient, precise cancer therapies, encouraging hospitals to invest in these high-tech platforms. Recent updates in states such as Arizona (effective August 2025) include reimbursement rules emphasizing radiation therapy management and dosimetry services critical to adaptive therapy, supporting advanced treatment adoption. These incentives help accelerate robotic radiotherapy penetration at oncologic centers by offsetting technology costs and encouraging precision care.
The industry has attracted significant investment, reflecting strong confidence in AI-powered, adaptive, and patient-centric treatment technologies. Funding is driving innovation in real-time imaging, adaptive treatment planning, and robotic delivery, enabling improved tumor targeting, workflow efficiency, and minimally invasive, outpatient-friendly therapies. Overall, this investment activity underscores growing investor confidence in technologies that enhance clinical outcomes and accelerate the adoption of advanced robotic radiotherapy worldwide.
Global Robotic Radiotherapy Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and analyzes industry trends in each sub-segment from 2021 to 2033. For this study, the analyst has segmented the global robotic radiotherapy market report based on product, technology, application, end use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Radiotherapy Systems
- Software
- 3D Cameras (Surface-Guided)
- Others
Technology Outlook (Revenue, USD Million, 2021-2033)
- Linear Accelerators
- Conventional Linear Accelerators
- MRI - Linear Accelerators
- Stereotactic Radiation Therapy Systems
- CyberKnife
- Gamma Knife
- Particle Therapy
- Proton Beam Therapy
- Heavy Ion Beam Therapy
Application Outlook (Revenue, USD Million, 2021-2033)
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Head & Neck Cancer
- Colorectal Cancer
- Other Cancers
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Independent Radiotherapy Centers
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Robotic Radiotherapy Market Variables, Trends & Scope
Chapter 4. Robotic Radiotherapy Market Segment Analysis, By Product, 2021-2033 (USD Million)
Chapter 5. Robotic Radiotherapy Market Segment Analysis, By Technology, 2021-2033 (USD Million)
Chapter 6. Robotic Radiotherapy Market Segment Analysis, By Application, 2021-2033 (USD Million)
Chapter 7. Robotic Radiotherapy Market Segment Analysis, By End Use, 2021-2033 (USD Million)
Chapter 8. Robotic Radiotherapy Market Segment Analysis, By Region, By Product, By Technology, By Application, By End Use, 2021-2033 (USD Million)
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The key companies profiled in this Robotic Radiotherapy market report include:- Varian, A Siemens Healthineers Company
- Elekta
- Accuray Incorporated
- ViewRay Technologies
- IBA
- Mevion Medical Systems
- Panacea Medical Technologies Pvt. Ltd.
- P-Cure
- ProNova Solutions, LLC
- Sumitomo Heavy Industries Ltd.
- Koninklijke Philips N.V.
- RaySearch Laboratories
- Vision RT Ltd.
- MIM Software Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | November 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.37 Billion |
| Forecasted Market Value ( USD | $ 3.3 Billion |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
